ChiCTR2300074392 版本V1.0 版本创建时间2023/08/04 17:09:08 中国临床试验注册中心

审核状态:

Project audit state:

通过审核

Successful

注册号:

Registration number:

ChiCTR2300074392 

最近更新日期:

Date of Last Refreshed on:

2023-08-04 17:08:36 

注册时间:

Date of Registration:

2023-08-04 00:00:00 

注册号状态:

预注册

Registration Status:

Prospective registration

注册题目:

基于多模态数据建立预测高血压患者的危险分层评分体系的研究

Public title:

Establishment of a risk stratification scoring system for predicting hypertensive patients based on multimodal data

注册题目简写:

English Acronym:

研究课题的正式科学名称:

基于多模态数据建立预测高血压患者的危险分层评分体系的研究

Scientific title:

Establishment of a risk stratification scoring system for predicting hypertensive patients based on multimodal data

研究课题代号(代码):

Study subject ID:

在二级注册机构或其它机构的注册号:

The registration number of the Partner Registry or other register:

申请注册联系人:

王钧 

研究负责人:

唐龙  

Applicant:

Jun Wang 

Study leader:

Long Tang  

申请注册联系人电话:

Applicant telephone:

+86 178 5613 0299

研究负责人电话:

Study leader's
telephone:

+86 189 5630 0320

申请注册联系人传真 :

Applicant Fax:

研究负责人传真:

Study leader's fax:

申请注册联系人电子邮件:

Applicant E-mail:

junwang0607@163.com

研究负责人电子邮件:

Study leader's E-mail:

812595591@qq.com

申请单位网址(自愿提供):

Applicant website(voluntary supply):

研究负责人网址(自愿提供):

Study leader's website(voluntary supply):

申请注册联系人通讯地址:

安徽省蚌埠市龙子湖区蚌埠医学院第一附属医院

研究负责人通讯地址:

安徽省宣城市宣州区宣城市人民医院内科楼6楼心血管内二科医生办公室

Applicant address:

The First Affiliated Hospital of Bengbu Medical College,Longzihu District,Bebgbu City,Anhui Province

Study leader's address:

15 Huancheng Road North, Xuanzhou District, Xuancheng, Anhui, China

申请注册联系人邮政编码:

Applicant postcode:

研究负责人邮政编码:

Study leader's postcode:

申请人所在单位:

安徽省蚌埠市龙子湖区蚌埠医学院第一附属医院

Applicant's institution:

The First Affiliated Hospital of Bengbu Medical College,Longzihu District,Bebgbu City,Anhui Province

研究负责人所在单位:

安徽省宣城市宣州区宣城市人民医院内科楼6楼心血管内二科医生办公室

Affiliation of the Leader:

15 Huancheng Road North, Xuanzhou District, Xuancheng, Anhui, China

是否获伦理委员会批准:

Approved by ethic committee:

Yes

伦理委员会批件文号:

Approved No. of ethic committee:

2023-1w008-01

伦理委员会批件附件:

Approved file of Ethical Committee:

查看附件View

批准本研究的伦理委员会名称:

宣城市人民医院临床研究伦理委员会

Name of the ethic committee:

Clinical Research Ethics Committee of Xuancheng People's Hospital

伦理委员会批准日期:

Date of approved by ethic committee:

2023-07-30 00:00:00

伦理委员会联系人:

张年宝

Contact Name of the ethic committee:

Nianbao Zhang

伦理委员会联系地址:

安徽省宣城市宣州区宣城市人民医院

Contact Address of the ethic committee:

15 Huancheng Road North, Xuanzhou District, Xuancheng, Anhui, China

伦理委员会联系人电话:

Contact phone of the ethic committee:

+86 181 5633 5568

伦理委员会联系人邮箱:

Contact email of the ethic committee:

研究实施负责(组长)单位:

宣城市人民医院

Primary sponsor:

The People's Hospital of Xuancheng City

研究实施负责(组长)单位地址:

安徽省宣城市宣州区环城北路15号

Primary sponsor's address:

15 Huancheng Road North, Xuanzhou District, Xuancheng, Anhui, China

试验主办单位(项目批准或申办者):

Secondary sponsor:

国家:

中国

省(直辖市):

安徽

市(区县):

Country:

China

Province:

Anhui

City:

单位(医院):

宣城市人民医院

具体地址:

安徽省宣城市宣州区环城北路15号

Institution
hospital:

The People's Hospital of Xuancheng City

Address:

15 Huancheng Road North, Xuanzhou District, Xuancheng, Anhui, China

经费或物资来源:

自筹经费

Source(s) of funding:

self-financing

研究疾病:

高血压  

Target disease:

Hypertension

研究疾病代码:

Target disease code:

研究类型:

观察性研究

Study type:

Observational study

研究所处阶段:

回顾性研究 

Study phase:

Retrospective study

研究设计:

连续入组 

Study design:

Sequential 

研究目的:

探讨高血压患者预后的影响因素,并基于多模态数据构建预测模型 模型,以便于早期识别主要不良心脑血管事件( Main Adverse Cardiovascular and Cerebrovascular Events, MACCEs ) 高风险的预测价值  

Objectives of Study:

To explore the factors influencing the prognosis of hypertensive patients and to construct a predictive model based on multimodal data Models for early identification of Main Adverse Cardiovascular and Cerebrovascular Events ( Main Adverse Cardiovascular and Cerebrovascular Events, MACCEs ) Predictive value of high-risk

药物成份或治疗方案详述:

 

Description for medicine or protocol of treatment in detail:

 

纳入标准:

1. 年龄为18-95岁之间; 2. 入院时诊断为高血压;

Inclusion criteria

1. age between 18 and 95 years; 2. a diagnosis of hypertension at the time of admission;

排除标准:

1. 继发性高血压; 2. 既往行冠状动脉搭桥手术; 3. 合并严重的心脏瓣膜疾病; 4. 活跃的心肌炎; 5.活跃的心包炎; 6. 有严重感染; 7. 严重肾功能不全(eGFR<30ml/min) 8. 风湿免疫系统疾病; 9. 精神上或法律上的丧失行为能力; 10.过去2年内滥用药物或酒精; 11. 基础心律非窦性节律患者(如心房扑动、心房颤动、严重房室传导阻滞及起搏器植入等; 12. 有肿瘤相关疾病; 13. 存在对自主神经功能有影响的其他疾病,如甲状腺功能亢进症、精神系统或者神经系统疾病等;

Exclusion criteria:

1. secondary hypertension; 2. prior coronary artery bypass graft surgery. 3. comorbid severe heart valve disease; 4. active myocarditis 5. active pericarditis 6. severe infections; 7. severe renal insufficiency (eg. 7. severe renal insufficiency (eGFR < 30 ml/min) 8. rheumatologic diseases; 9. mental or legal incapacity. 10. drug or alcohol abuse within the last 2 years. 11. patients with an underlying rhythm other than sinus rhythm (e.g., atrial flutter, atrial fibrillation, severe atrioventricular block, and pacemaker implantation; 12. the presence of tumor-related diseases 13. the presence of other diseases that have an impact on autonomic function, such as hyperthyroidism, psychiatric or neurological disorders.

研究实施时间:

Study execute time:

From 2023-08-06 00:00:00 To 2023-09-30 00:00:00  

征募观察对象时间:

Recruiting time:

From 2023-08-06 00:00:00 To 2023-08-31 00:00:00

干预措施:

Interventions:

组别:

高血压组

样本量:

1000

Group:

hypertensive group

Sample size:

干预措施:

干预措施代码:

Intervention:

NA

Intervention code:

研究实施地点:

Countries of recruitment and research settings:

国家:

中国

省(直辖市):

安徽 

市(区县):

 

Country:

China

Province:

Anhui

City:

单位(医院):

宣城市人民医院  

单位级别:

三甲 

Institution
hospital:

Xuancheng City People's Hospital

Level of the institution:

Tertiary A

测量指标:

Outcomes:

指标中文名:

高血压患者随访发现不良心血管事件

指标类型:

主要指标

Outcome:

Main Adverse Cardiovascular and Cerebrovascular Events ( Main Adverse Cardiovascular and Cerebrovascular Events, MACCEs ) detected on follow-up

Type:

Primary indicator

测量时间点:

一年,两年,三年

测量方法:

Measure time point of outcome:

One year, two years, three years.

Measure method:

指标中文名:

高血压患者常规基线资料及入院检查的资料

指标类型:

主要指标

Outcome:

Routine baseline data of hypertensive patients and data from hospital admission tests

Type:

Primary indicator

测量时间点:

测量方法:

Measure time point of outcome:

Measure method:

采集人体标本:

Collecting sample(s)
from participants:

标本中文名:

组织:

Sample Name:

NA

Tissue:

人体标本去向

其它  

说明

Fate of sample:

0thers  

Note:

征募研究对象情况:

Recruiting status:

正在进行

Recruiting

年龄范围:

Participant age:

最小 Min age 18 years
最大 Max age 95 years

性别:

男女均可

Gender:

Both

随机方法(请说明由何人用什么方法产生随机序列):

Randomization Procedure (please state who generates the random number sequence and by what method):

NA

是否公开试验完成后的统计结果:

Calculated Results after the Study Completed public access:

不公开/Private

盲法:

Blinding:

是否共享原始数据:

IPD sharing

否No

共享原始数据的方式(说明:请填入公开原始数据日期和方式,如采用网络平台,需填该网络平台名称和网址):

The way of sharing IPD”(include metadata and protocol, If use web-based public database, please provide the url):

NA

数据采集和管理(说明:数据采集和管理由两部分组成,一为病例记录表(Case Record Form, CRF),二为电子采集和管理系统(Electronic Data Capture, EDC),如ResMan即为一种基于互联网的EDC:

数据由病例记录表和电子采集系统采集和管理

Data collection and Management (A standard data collection and management system include a CRF and an electronic data capture:

Data is captured and managed by case record forms and electronic capture systems

数据与安全监察委员会:

Data and Safety Monitoring Committee:

暂未确定/Not yet

注册人:

Name of Registration:

 2023-08-04 17:08:36